Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AllianzGI Health Sciences Fund Class B (RBGHX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio managers consider health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences or that otherwise promote healthy living. The fund will invest primarily in common stocks and other equity securities.


1 month+3.52% 3 years+22.62%
3 months+2.27% 5 years+18.32%
1 year+10.63% Since inception+7.93%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+18.32%+20.66%
Expense ratio2.21%1.39%
Risk 5 year sharpe ratio1.361.42
Net assets$66.1M$3.8B
Average market cap$28.1B$35.0B
Average P/E24.424.4
Portfolio turnover76%76%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyAllianz Funds
Fund manager & tenureMichael Dauchot / 10 Years
Minimal initial investment$1,000.00
Minimum IRA investment$1,000.00


U.S. stock84.30%
International stock11.80%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 81.95%
Consumer goods 9.88%
Consumer service 4.31%
Hardware 2.62%
Business service 0.00%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth4.21%
CELG Celgene3.74%
ABBV AbbVie3.29%
EGRX Eagle Pharmaceuticals Inc3.09%
ALXN Alexion Pharmaceuticals Inc3.08%
REGN Regeneron Pharmaceuticals3.02%
BMY Bristol-Myers Squibb2.96%
MYL Mylan NV2.75%
VRTX Vertex Pharmaceuticals Inc2.70%
-- 2.65%